Dr. Changqing Li, Co-founder & CMO of Eglin Pharma, Shares Insights on FDA's AI-Driven Review Trends and Strategic Responses

Dr. Li Changqing holds a Master's degree in Hospital Management from the University of Alabama at Birmingham and a Doctorate in Public Health. He is a licensed physician in the United States and has obtained certification as a specialist in clinical pathology. He once served as a senior medical reviewer at the U.S. FDA and was the first Chinese international student to enter the FDA’s clinical review process as a physician. Dr. Li has extensive global clinical trial experience ranging from Phase I to Phase IV studies in areas such as oncology, immunotherapy, anti-inflammatory treatments, gastrointestinal diseases, and gynecological conditions. He has led hundreds of clinical trials worldwide and over 30 new drug applications.